Recombinant Human KARS (C-6His)

Description

EnkiLife provides the Recombinant Human KARS (C-6His) protein,aslo know as Lysine--tRNA Ligase,Lysyl-tRNA Synthetase,LysRS,KARS,KIAA0070, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Lysine-tRNA Ligase is produced by our Mammalian expression system and the target gene encoding Ala2-Val597 is expressed with a 6His tag at the C-terminus.Accession:Q15046. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:69.1 KDa. Background:Lysine-tRNA ligase, also known as Lysyl-tRNA synthetase, LysRS, KARS and KIAA0070, belongs to the class-II aminoacyl-tRNA synthetase family. The N-terminal cytoplasmic domain (1-65) is a functional tRNA-binding domain, which is required for nuclear localization, is involved in the interaction with DARS, but has a repulsive role in the binding to EEF1A1. A central domain (208-259) is involved in homodimerization and is required for interaction with HIV-1 GAG and incorporation into virions. KARS catalyzes the specific attachment of an amino acid to its cognate tRNA in a two step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA. Defects in KARS are the cause of Charcot-Marie-Tooth disease recessive intermediate type B (CMTRIB).